Crohn's Disease and Colitis Trial, Recruiting NCT06696014 Sponsor: University of North Carolina, Chapel Hill Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT06696014
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have been diagnosed with ulcerative colitis (a condition causing inflammation of the large intestine) and have either started a medication called mirikizumab within the last 2 weeks, or are planning to start it within the next 2 weeks, as part of their standard medical care.
  • People whose diagnosis of ulcerative colitis is confirmed through standard medical tests including clinical assessment, imaging, a camera examination of the bowel, and tissue samples.
  • People who have experienced symptoms such as diarrhoea, rectal bleeding, abdominal pain, fever, weight loss, or related symptoms on more than one occasion at least 8 weeks apart, or continuously for at least 6 weeks.
  • People whose bowel camera examination shows inflammation starting from the rectum and spreading upward in a continuous pattern, without signs of a related but different condition called Crohn's disease.
  • People who are expected to continue being seen and monitored at the participating clinic for the next 12 months.

Who may not be able to join:

  • People who are unable to give their own informed consent to participate.
  • People who do not speak English.
  • People who are attending the clinic for a single consultation only and are not regular patients there.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Hans Herfarth, MD, PhD, University of North Carolina

Phone: 919-843-8105

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
8 May 2025
Est. completion
1 January 2030

Where this trial is recruiting

🇨🇦 Canada 🇺🇸 United States

Primary endpoints

induction of clinical response as evaluated by the Simple Clinical Colitis Activity Index (SCCAI) for the patient-reported outcomes.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov